• Annals of surgery · Nov 2023

    Textbook Oncological Outcome in European Gastrodata.

    • Katarzyna Sędłak, Karol Rawicz-Pruszyński, Radosław Mlak, Johanna Van Sandick, Suzanne Gisbertz, Manuel Pera, Dal CeroMariagiuliaMDepartment of Digestive Surgery, Hospital Universitario del Mar, Barcelona, Spain., Gian Luca Baiocchi, Andrea Celotti, Paolo Morgagni, Giovani Vittimberga, Arnulf Hoelscher, Stefan Moenig, Piotr Kołodziejczyk, Piotr Richter, Ines Gockel, Guillaume Piessen, Paulo Matos Da Costa, Andrew Davies, Cara Baker, William Allum, RomarioUberto FumagalliUFDigestive Surgery, European Institute of Oncology, IRCCS, Milan, Italy., Stefano De Pascale, Ricccardo Rosati, Daniel Reim, Lucio Lara Santos, Domenico D'ugo, Bas Wijnhoven, Maurizio Degiuli, Giovanni De Manzoni, Wojciech Kielan, Ewelina Frejlich, Paul Schneider, and Wojciech P Polkowski.
    • Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
    • Ann. Surg. 2023 Nov 1; 278 (5): 823831823-831.

    ObjectiveTo assess the rate of textbook outcome (TO) and textbook oncological outcome (TOO) in the European population based on the GASTRODATA registry.BackgroundTO is a composite parameter assessing surgical quality and strongly correlates with improved overall survival. Following the standard of treatment for locally advanced gastric cancer, TOO was proposed as a quality and optimal multimodal treatment parameter.MethodsTO was achieved when all the following criteria were met: no intraoperative complications, radical resection according to the surgeon, pR0 resection, retrieval of at least 15 lymph nodes, no severe postoperative complications, no reintervention, no admission to the intensive care unit, no prolonged length of stay, no postoperative mortality and no hospital readmission. TOO was defined as TO with the addition of perioperative chemotherapy compliance.ResultsOf the 2558 patients, 1700 were included in the analysis. TO was achieved in 1164 (68.5%) patients. The use of neoadjuvant chemotherapy [odds ratio (OR) = 1.33, 95% CI: 1.04-1.70] and D2 or D2+ lymphadenectomy (OR = 1.55, 95% CI: 1.15-2.10) had a positive impact on TO achievement. Older age (OR = 0.73, 95% CI: 0.54-0.94), pT3/4 (OR = 0.79, 95% CI: 0.63-0.99), ASA 3/4 (OR = 0.68, 95% CI: 0.54-0.86) and total gastrectomy (OR = 0.56, 95% CI: 0.45-0.70), had a negative impact on TO achievement. TOO was achieved in 388 (22.8%) patients. Older age (OR = 0.37, 95% CI: 0.27-0.53), pT3 or pT4 (OR = 0.52, 95% CI: 0.39-0.69), and ASA 3 or 4 (OR = 0.58, 95% CI: 0.43-0.79) had a negative impact on TOO achievement.ConclusionsDespite successively improved surgical outcomes, stage-appropriate chemotherapy in adherence to the current guidelines for multimodal treatment of gastric cancer remains poor. Further implementation of oncologic quality metrics should include greater emphasis on perioperative chemotherapy and adequate lymphadenectomy.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.